The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Scleroderma Therapeutics Market Research Report 2025

Global Scleroderma Therapeutics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1707312

No of Pages : 92

Ask Your Query

Synopsis

Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.

The global Scleroderma Therapeutics market was valued at US$ 1402.3 million in 2023 and is anticipated to reach US$ 1827.1 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Scleroderma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Scleroderma Therapeutics.

Report Scope

The Scleroderma Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Scleroderma Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Scleroderma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company (Partial List):

  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Argentis Pharmaceuticals, LLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Akashi Therapeutics
  • Prometic Life Sciences, Inc.
  • Emerald Health Pharmaceuticals
  • Kadmon Holdings, Inc.
  • Seattle Genetics, Inc.
  • Cytori Therapeutics, Inc.
  • Fibrocell Science, Inc.
  • Chemomab
  • Corbus Pharmaceuticals Holdings, Inc.
  • Genkyotex

Segment by Type

  • Immunosuppressors
  • Phosphodiesterase 5 Inhibitors - PHA
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Calcium Channel Blockers
  • Analgesics
  • Others

Segment by Application

  • Systemic
  • Localized

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil,Turkey, GCC Countries)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Scleroderma Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Immunosuppressors

1.2.3 Phosphodiesterase 5 Inhibitors - PHA

1.2.4 Endothelin Receptor Antagonists

1.2.5 Prostacyclin Analogues

1.2.6 Calcium Channel Blockers

1.2.7 Analgesics

1.2.8 Others

1.3 Market by Application

1.3.1 Global Scleroderma Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Systemic

1.3.3 Localized

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Scleroderma Therapeutics Market Perspective (2019-2030)

2.2 Scleroderma Therapeutics Growth Trends by Region

2.2.1 Global Scleroderma Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Scleroderma Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Scleroderma Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Scleroderma Therapeutics Market Dynamics

2.3.1 Scleroderma Therapeutics Industry Trends

2.3.2 Scleroderma Therapeutics Market Drivers

2.3.3 Scleroderma Therapeutics Market Challenges

2.3.4 Scleroderma Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Scleroderma Therapeutics Players by Revenue

3.1.1 Global Top Scleroderma Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Scleroderma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Scleroderma Therapeutics Revenue

3.4 Global Scleroderma Therapeutics Market Concentration Ratio

3.4.1 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Scleroderma Therapeutics Revenue in 2023

3.5 Scleroderma Therapeutics Key Players Head office and Area Served

3.6 Key Players Scleroderma Therapeutics Product Solution and Service

3.7 Date of Enter into Scleroderma Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Scleroderma Therapeutics Breakdown Data by Type

4.1 Global Scleroderma Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Scleroderma Therapeutics Forecasted Market Size by Type (2025-2030)

5 Scleroderma Therapeutics Breakdown Data by Application

5.1 Global Scleroderma Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Scleroderma Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Scleroderma Therapeutics Market Size (2019-2030)

6.2 North America Scleroderma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Scleroderma Therapeutics Market Size by Country (2019-2024)

6.4 North America Scleroderma Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Scleroderma Therapeutics Market Size (2019-2030)

7.2 Europe Scleroderma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Scleroderma Therapeutics Market Size by Country (2019-2024)

7.4 Europe Scleroderma Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Scleroderma Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Scleroderma Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Scleroderma Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Scleroderma Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Scleroderma Therapeutics Market Size (2019-2030)

9.2 Latin America Scleroderma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Scleroderma Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Scleroderma Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Scleroderma Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Scleroderma Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Scleroderma Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Scleroderma Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 F. Hoffmann-La Roche AG

11.1.1 F. Hoffmann-La Roche AG Company Detail

11.1.2 F. Hoffmann-La Roche AG Business Overview

11.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Introduction

11.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2019-2024)

11.1.5 F. Hoffmann-La Roche AG Recent Development

11.2 Bristol-Myers Squibb Company

11.2.1 Bristol-Myers Squibb Company Company Detail

11.2.2 Bristol-Myers Squibb Company Business Overview

11.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Introduction

11.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2019-2024)

11.2.5 Bristol-Myers Squibb Company Recent Development

11.3 Celgene Corporation

11.3.1 Celgene Corporation Company Detail

11.3.2 Celgene Corporation Business Overview

11.3.3 Celgene Corporation Scleroderma Therapeutics Introduction

11.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2019-2024)

11.3.5 Celgene Corporation Recent Development

11.4 Argentis Pharmaceuticals, LLC

11.4.1 Argentis Pharmaceuticals, LLC Company Detail

11.4.2 Argentis Pharmaceuticals, LLC Business Overview

11.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Introduction

11.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2019-2024)

11.4.5 Argentis Pharmaceuticals, LLC Recent Development

11.5 Bayer AG

11.5.1 Bayer AG Company Detail

11.5.2 Bayer AG Business Overview

11.5.3 Bayer AG Scleroderma Therapeutics Introduction

11.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2019-2024)

11.5.5 Bayer AG Recent Development

11.6 Boehringer Ingelheim International GmbH

11.6.1 Boehringer Ingelheim International GmbH Company Detail

11.6.2 Boehringer Ingelheim International GmbH Business Overview

11.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Introduction

11.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2019-2024)

11.6.5 Boehringer Ingelheim International GmbH Recent Development

11.7 Akashi Therapeutics

11.7.1 Akashi Therapeutics Company Detail

11.7.2 Akashi Therapeutics Business Overview

11.7.3 Akashi Therapeutics Scleroderma Therapeutics Introduction

11.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2019-2024)

11.7.5 Akashi Therapeutics Recent Development

11.8 Prometic Life Sciences, Inc.

11.8.1 Prometic Life Sciences, Inc. Company Detail

11.8.2 Prometic Life Sciences, Inc. Business Overview

11.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Introduction

11.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.8.5 Prometic Life Sciences, Inc. Recent Development

11.9 Emerald Health Pharmaceuticals

11.9.1 Emerald Health Pharmaceuticals Company Detail

11.9.2 Emerald Health Pharmaceuticals Business Overview

11.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Introduction

11.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2019-2024)

11.9.5 Emerald Health Pharmaceuticals Recent Development

11.10 Kadmon Holdings, Inc.

11.10.1 Kadmon Holdings, Inc. Company Detail

11.10.2 Kadmon Holdings, Inc. Business Overview

11.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Introduction

11.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.10.5 Kadmon Holdings, Inc. Recent Development

11.11 Seattle Genetics, Inc.

11.11.1 Seattle Genetics, Inc. Company Detail

11.11.2 Seattle Genetics, Inc. Business Overview

11.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Introduction

11.11.4 Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.11.5 Seattle Genetics, Inc. Recent Development

11.12 Cytori Therapeutics, Inc.

11.12.1 Cytori Therapeutics, Inc. Company Detail

11.12.2 Cytori Therapeutics, Inc. Business Overview

11.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Introduction

11.12.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.12.5 Cytori Therapeutics, Inc. Recent Development

11.13 Fibrocell Science, Inc.

11.13.1 Fibrocell Science, Inc. Company Detail

11.13.2 Fibrocell Science, Inc. Business Overview

11.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Introduction

11.13.4 Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.13.5 Fibrocell Science, Inc. Recent Development

11.14 Chemomab

11.14.1 Chemomab Company Detail

11.14.2 Chemomab Business Overview

11.14.3 Chemomab Scleroderma Therapeutics Introduction

11.14.4 Chemomab Revenue in Scleroderma Therapeutics Business (2019-2024)

11.14.5 Chemomab Recent Development

11.15 Corbus Pharmaceuticals Holdings, Inc.

11.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Detail

11.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview

11.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Introduction

11.15.4 Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024)

11.15.5 Corbus Pharmaceuticals Holdings, Inc. Recent Development

11.16 Genkyotex

11.16.1 Genkyotex Company Detail

11.16.2 Genkyotex Business Overview

11.16.3 Genkyotex Scleroderma Therapeutics Introduction

11.16.4 Genkyotex Revenue in Scleroderma Therapeutics Business (2019-2024)

11.16.5 Genkyotex Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

List of Tables

Table 1. Global Scleroderma Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Immunosuppressors

Table 3. Key Players of Phosphodiesterase 5 Inhibitors - PHA

Table 4. Key Players of Endothelin Receptor Antagonists

Table 5. Key Players of Prostacyclin Analogues

Table 6. Key Players of Calcium Channel Blockers

Table 7. Key Players of Analgesics

Table 8. Key Players of Others

Table 9. Global Scleroderma Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 10. Global Scleroderma Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 11. Global Scleroderma Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 12. Global Scleroderma Therapeutics Market Share by Region (2019-2024)

Table 13. Global Scleroderma Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 14. Global Scleroderma Therapeutics Market Share by Region (2025-2030)

Table 15. Scleroderma Therapeutics Market Trends

Table 16. Scleroderma Therapeutics Market Drivers

Table 17. Scleroderma Therapeutics Market Challenges

Table 18. Scleroderma Therapeutics Market Restraints

Table 19. Global Scleroderma Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 20. Global Scleroderma Therapeutics Market Share by Players (2019-2024)

Table 21. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Scleroderma Therapeutics as of 2023)

Table 22. Ranking of Global Top Scleroderma Therapeutics Companies by Revenue (US$ Million) in 2023

Table 23. Global 5 Largest Players Market Share by Scleroderma Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 24. Key Players Headquarters and Area Served

Table 25. Key Players Scleroderma Therapeutics Product Solution and Service

Table 26. Date of Enter into Scleroderma Therapeutics Market

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Scleroderma Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 29. Global Scleroderma Therapeutics Revenue Market Share by Type (2019-2024)

Table 30. Global Scleroderma Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 31. Global Scleroderma Therapeutics Revenue Market Share by Type (2025-2030)

Table 32. Global Scleroderma Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 33. Global Scleroderma Therapeutics Revenue Market Share by Application (2019-2024)

Table 34. Global Scleroderma Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 35. Global Scleroderma Therapeutics Revenue Market Share by Application (2025-2030)

Table 36. North America Scleroderma Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. North America Scleroderma Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 38. North America Scleroderma Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 39. Europe Scleroderma Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 40. Europe Scleroderma Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 41. Europe Scleroderma Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 42. Asia-Pacific Scleroderma Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 43. Asia-Pacific Scleroderma Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 44. Asia-Pacific Scleroderma Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 45. Latin America Scleroderma Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Latin America Scleroderma Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 47. Latin America Scleroderma Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 48. Middle East & Africa Scleroderma Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 49. Middle East & Africa Scleroderma Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 50. Middle East & Africa Scleroderma Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 51. F. Hoffmann-La Roche AG Company Detail

Table 52. F. Hoffmann-La Roche AG Business Overview

Table 53. F. Hoffmann-La Roche AG Scleroderma Therapeutics Product

Table 54. F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 55. F. Hoffmann-La Roche AG Recent Development

Table 56. Bristol-Myers Squibb Company Company Detail

Table 57. Bristol-Myers Squibb Company Business Overview

Table 58. Bristol-Myers Squibb Company Scleroderma Therapeutics Product

Table 59. Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 60. Bristol-Myers Squibb Company Recent Development

Table 61. Celgene Corporation Company Detail

Table 62. Celgene Corporation Business Overview

Table 63. Celgene Corporation Scleroderma Therapeutics Product

Table 64. Celgene Corporation Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 65. Celgene Corporation Recent Development

Table 66. Argentis Pharmaceuticals, LLC Company Detail

Table 67. Argentis Pharmaceuticals, LLC Business Overview

Table 68. Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Product

Table 69. Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 70. Argentis Pharmaceuticals, LLC Recent Development

Table 71. Bayer AG Company Detail

Table 72. Bayer AG Business Overview

Table 73. Bayer AG Scleroderma Therapeutics Product

Table 74. Bayer AG Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 75. Bayer AG Recent Development

Table 76. Boehringer Ingelheim International GmbH Company Detail

Table 77. Boehringer Ingelheim International GmbH Business Overview

Table 78. Boehringer Ingelheim International GmbH Scleroderma Therapeutics Product

Table 79. Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 80. Boehringer Ingelheim International GmbH Recent Development

Table 81. Akashi Therapeutics Company Detail

Table 82. Akashi Therapeutics Business Overview

Table 83. Akashi Therapeutics Scleroderma Therapeutics Product

Table 84. Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 85. Akashi Therapeutics Recent Development

Table 86. Prometic Life Sciences, Inc. Company Detail

Table 87. Prometic Life Sciences, Inc. Business Overview

Table 88. Prometic Life Sciences, Inc. Scleroderma Therapeutics Product

Table 89. Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 90. Prometic Life Sciences, Inc. Recent Development

Table 91. Emerald Health Pharmaceuticals Company Detail

Table 92. Emerald Health Pharmaceuticals Business Overview

Table 93. Emerald Health Pharmaceuticals Scleroderma Therapeutics Product

Table 94. Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 95. Emerald Health Pharmaceuticals Recent Development

Table 96. Kadmon Holdings, Inc. Company Detail

Table 97. Kadmon Holdings, Inc. Business Overview

Table 98. Kadmon Holdings, Inc. Scleroderma Therapeutics Product

Table 99. Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 100. Kadmon Holdings, Inc. Recent Development

Table 101. Seattle Genetics, Inc. Company Detail

Table 102. Seattle Genetics, Inc. Business Overview

Table 103. Seattle Genetics, Inc. Scleroderma Therapeutics Product

Table 104. Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 105. Seattle Genetics, Inc. Recent Development

Table 106. Cytori Therapeutics, Inc. Company Detail

Table 107. Cytori Therapeutics, Inc. Business Overview

Table 108. Cytori Therapeutics, Inc. Scleroderma Therapeutics Product

Table 109. Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 110. Cytori Therapeutics, Inc. Recent Development

Table 111. Fibrocell Science, Inc. Company Detail

Table 112. Fibrocell Science, Inc. Business Overview

Table 113. Fibrocell Science, Inc. Scleroderma Therapeutics Product

Table 114. Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 115. Fibrocell Science, Inc. Recent Development

Table 116. Chemomab Company Detail

Table 117. Chemomab Business Overview

Table 118. Chemomab Scleroderma Therapeutics Product

Table 119. Chemomab Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 120. Chemomab Recent Development

Table 121. Corbus Pharmaceuticals Holdings, Inc. Company Detail

Table 122. Corbus Pharmaceuticals Holdings, Inc. Business Overview

Table 123. Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Product

Table 124. Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 125. Corbus Pharmaceuticals Holdings, Inc. Recent Development

Table 126. Genkyotex Company Detail

Table 127. Genkyotex Business Overview

Table 128. Genkyotex Scleroderma Therapeutics Product

Table 129. Genkyotex Revenue in Scleroderma Therapeutics Business (2019-2024) & (US$ Million)

Table 130. Genkyotex Recent Development

Table 131. Research Programs/Design for This Report

Table 132. Key Data Information from Secondary Sources

Table 133. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Scleroderma Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Scleroderma Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Immunosuppressors Features

Figure 4. Phosphodiesterase 5 Inhibitors - PHA Features

Figure 5. Endothelin Receptor Antagonists Features

Figure 6. Prostacyclin Analogues Features

Figure 7. Calcium Channel Blockers Features

Figure 8. Analgesics Features

Figure 9. Others Features

Figure 10. Global Scleroderma Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 11. Global Scleroderma Therapeutics Market Share by Application: 2023 VS 2030

Figure 12. Systemic Case Studies

Figure 13. Localized Case Studies

Figure 14. Scleroderma Therapeutics Report Years Considered

Figure 15. Global Scleroderma Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Scleroderma Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Scleroderma Therapeutics Market Share by Region: 2023 VS 2030

Figure 18. Global Scleroderma Therapeutics Market Share by Players in 2023

Figure 19. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Scleroderma Therapeutics as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Scleroderma Therapeutics Revenue in 2023

Figure 21. North America Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Scleroderma Therapeutics Market Share by Country (2019-2030)

Figure 23. United States Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Scleroderma Therapeutics Market Share by Country (2019-2030)

Figure 27. Germany Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Scleroderma Therapeutics Market Share by Region (2019-2030)

Figure 35. China Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Japan Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. South Korea Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Southeast Asia Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. India Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Australia Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Scleroderma Therapeutics Market Share by Country (2019-2030)

Figure 43. Mexico Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Brazil Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Scleroderma Therapeutics Market Share by Country (2019-2030)

Figure 47. Turkey Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Scleroderma Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. F. Hoffmann-La Roche AG Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 50. Bristol-Myers Squibb Company Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 51. Celgene Corporation Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 52. Argentis Pharmaceuticals, LLC Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 53. Bayer AG Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 54. Boehringer Ingelheim International GmbH Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 55. Akashi Therapeutics Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 56. Prometic Life Sciences, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 57. Emerald Health Pharmaceuticals Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 58. Kadmon Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 59. Seattle Genetics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 60. Cytori Therapeutics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 61. Fibrocell Science, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 62. Chemomab Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 63. Corbus Pharmaceuticals Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 64. Genkyotex Revenue Growth Rate in Scleroderma Therapeutics Business (2019-2024)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock